FDA Brief

Warning letters Drugs

FDA warning letter to

Dynamic Health Group dba SARMS AMERICA

High riskIssued Dec 12, 2025Posted Dec 23, 2025Center for Drug Evaluation and Research (CDER)

FDA told SARMS AMERICA its SARMs products (Ostarine, MK-677, Cardarine, LGD-4033) are unapproved new drugs sold online without FDA approval.

What happened

FDA reviewed the company's website at https://sarmsamerica.co/ in November 2025; no plant inspection took place. The review found the site selling products marketed as selective androgen receptor modulators (SARMs) — chemicals sold for muscle growth and fat loss — with statements about treating conditions and changing how the body works. FDA says those statements make the products drugs, and that no approved application exists for them, so selling them across state lines breaks the law.

What FDA found

  1. The products are unapproved new drugs because FDA has not approved any application for them, yet they are offered for sale across state lines.

    sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  2. The products are 'new drugs' because they are not generally recognized as safe and effective for the uses described in their labeling.

    section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. Website claims about muscle growth, fat loss, bone density, heart health and hormone levels show the products are intended to affect the body or treat disease, which makes them drugs.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  4. Saying the products are 'for research use only' does not undo the drug claims made elsewhere on the same website.

    21 CFR 201.128

What FDA wants

FDA asks the company to write back within fifteen working days describing the specific steps taken to fix the violations, how it will prevent them from happening again, and copies of related documents. If corrective action cannot be finished in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • online sellers of SARMs and research chemicals marketed for human use
  • supplement and fitness brands that link to or resell these products
  • consumers and athletes buying SARMs over the internet

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk